<DOC>
	<DOCNO>NCT01924299</DOCNO>
	<brief_summary>The main purpose study look effect ketoconazole fluconazole much baricitinib get blood stream . The study also look tolerability baricitinib ketoconazole give together tolerability baricitinib fluconazole give together . Participants recruit one 2 treatment group ( Group A , Group B ) . Each treatment group participate 2 study period . Participants take baricitinib alone one period baricitinib either ketaconazole fluconazole period . This study last approximately 7 week .</brief_summary>
	<brief_title>A Study Baricitinib When Administered With Ketoconazole Fluconazole Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Overtly healthy determine medical history physical examination Female participant childbearing potential due surgical sterilization ( least 3 month surgical hysterectomy , bilateral oophorectomy without hysterectomy , bilateral tubal occlusion/ligation ) confirm medical history menopause Have body mass index 18 29 kilogram per square meter ( kg/m^2 ) , inclusive , screen Participants previously complete withdrawn study study investigate baricitinib , previously receive study drug Have know allergy baricitinib , ketoconazole , fluconazole , related compound , component baricitinib , ketoconazole , fluconazole formulation , history significant atopy Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have current recent history ( le 30 day prior screen and/or less 45 day prior day admission clinical research unit ) clinically significant bacterial , fungal , parasitic , viral ( include rhinopharyngitis ) , mycobacterial infection Have alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , total bilirubin , gamma glutamyl transferase ( GGT ) value upper limit reference range local laboratory screen day admission clinical research unit Have absolute neutrophil count ( ANC ) less 2 time 10^9 per liter ( L ) ( 2000 cell per microliter [ Î¼L ] ) screen day admission clinical research unit . For abnormal value , single repeat allow Intend use overthecounter prescription medication and/or herbal supplement within 14 day prior dose study ( exception occasional paracetamol , permit discretion investigator ) , intend use vitamin supplement Day 1 discharge Clinical Research Unit ( CRU ) Have use intend use drug substance know substrate , inhibitor , inducer cytochrome P450 ( CYP ) 3A4 , CYP2C9 , CYP2C19 within 30 day prior dose throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>